Investigational Drug Information for Carisbamate
What is the development status for investigational drug Carisbamate?
Carisbamate is an investigational drug.
There have been 15 clinical trials for Carisbamate.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2022.
The most common disease conditions in clinical trials are Epilepsy, Epilepsies, Partial, and Seizures. The leading clinical trial sponsors are SK Life Science, Inc., SK Life Science, and Baylor College of Medicine.
Summary for Carisbamate
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 207 |
| WIPO Patent Applications | 111 |
| Japanese Patent Applications | 13 |
| Clinical Trial Progress | Phase 3 (2022-02-01) |
| Vendors | 35 |
Recent Clinical Trials for Carisbamate
| Title | Sponsor | Phase |
|---|---|---|
| Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults | SK Life Science, Inc. | Phase 3 |
| Bioavailability and Food Effect Study of 3 Types of Carisbamate | PRA Health Sciences | Phase 1 |
| Bioavailability and Food Effect Study of 3 Types of Carisbamate | SK Life Science, Inc. | Phase 1 |
Clinical Trial Summary for Carisbamate
Top disease conditions for Carisbamate
Top clinical trial sponsors for Carisbamate
US Patents for Carisbamate
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Carisbamate is a discontinued investigational antiseizure drug with no FDA approval, no commercial sales, and no active branded market. Johnson & Johnson and its Janssen subsidiary advanced carisbamate, also known as RWJ-333369, into Phase III trials for partial-onset seizures, but development was stopped after the program failed to establish a viable efficacy and safety profile. The near-term market projection is therefore zero unless a new sponsor revives the compound and generates new clinical data.
Carisbamate Development Update and Market Projection
What is the current development status of carisbamate?
Carisbamate is an investigational small-molecule antiepileptic drug that reached late-stage clinical development but was not approved by the U.S. Food and Drug Administration.
The compound was developed primarily for epilepsy, including refractory partial-onset seizures. Public clinical records identify it as carisbamate and RWJ-333369. The program included randomized Phase II and Phase III studies evaluating carisbamate as adjunctive therapy in patients whose seizures were inadequately controlled by existing antiseizure medicines. ClinicalTrials.gov records classify the principal studies as completed rather than ongoing or recruiting (ClinicalTrials.gov, n.d.-a; ClinicalTrials.gov, n.d.-b).
The development program did not produce a commercial launch. There is no FDA-approved carisbamate product, no established brand, and no active U.S. prescription market.
Carisbamate development timeline
| Period | Development event | Commercial significance |
|---|---|---|
| Early 2000s | Carisbamate entered clinical development as RWJ-333369 | Program positioned as a new antiseizure therapy |
| Mid-2000s | Phase II studies evaluated adjunctive treatment in partial-onset seizures | Evidence supported advancement to larger studies |
| 2006-2008 | Phase III studies assessed efficacy and tolerability in refractory epilepsy | Program required a clinically differentiated benefit to compete in a crowded market |
| 2008-2009 | Sponsor discontinued further development after unfavorable late-stage results | No NDA approval or commercial launch followed |
| 2010 onward | No meaningful clinical reactivation has been publicly documented | Asset has no established development or revenue trajectory |
The exact discontinuation date is reported differently across secondary sources, but the strategic outcome is consistent: the sponsor did not continue carisbamate toward approval after the Phase III program.
Why was carisbamate development discontinued?
The principal issue was inadequate late-stage clinical performance relative to the requirements for approval and commercial differentiation.
Carisbamate was tested in patients with refractory epilepsy, a population in which placebo response, treatment resistance, concomitant medications, and tolerability can materially affect trial outcomes. The Phase III program did not establish a sufficiently attractive benefit-risk profile for continued development.
The commercial environment also reduced the asset’s value. By the time the program reached late-stage development, physicians had access to multiple branded and generic antiseizure drugs, including levetiracetam, lamotrigine, topiramate, oxcarbazepine, lacosamide and others. A new product would have needed a clear advantage in seizure reduction, cognitive tolerability, drug-drug interactions, dosing convenience, or safety.
What were the clinical indications for carisbamate?
The principal clinical target was adjunctive treatment of partial-onset seizures in adults with epilepsy.
Publicly documented studies included patients with refractory partial-onset seizures. Carisbamate was not approved for:
- Generalized epilepsy
- Status epilepticus
- Migraine prevention
- Bipolar disorder
- Neuropathic pain
- Pediatric epilepsy
- Monotherapy epilepsy treatment
Some investigational antiseizure compounds are evaluated across multiple neurological indications. The publicly supported carisbamate program, however, centered on epilepsy rather than a broad multi-indication franchise.
Did carisbamate receive FDA approval or regulatory exclusivity?
No. Carisbamate did not receive FDA approval, new chemical entity exclusivity, orphan-drug exclusivity, pediatric exclusivity, or other U.S. regulatory exclusivity linked to an approved product.
What is the FDA regulatory status of carisbamate?
| FDA regulatory category | Carisbamate status |
|---|---|
| Approved drug | No |
| Approved active ingredient | No |
| FDA Orange Book listing | No approved product listing identified |
| NDA approval | No public approval |
| Abbreviated New Drug Application pathway | Not applicable |
| Regulatory exclusivity | None attached to an approved product |
| U.S. commercial launch | None |
Because carisbamate was never approved, an applicant could not rely on an abbreviated new drug application referencing a marketed carisbamate product. A future sponsor would likely need to establish a new regulatory pathway through a full investigational and NDA program, unless it obtained access to qualifying prior data and negotiated a different development strategy with FDA.
FDA’s Orange Book lists approved drug products and associated patent and exclusivity information. An unapproved development candidate does not have an Orange Book commercial listing (U.S. Food and Drug Administration, n.d.-a).
What patents protect carisbamate?
Carisbamate was protected during development by compound, formulation and potentially use-related patent rights held by the originator or affiliated entities. The commercially relevant issue is that patent protection does not create market exclusivity without regulatory approval.
No active Orange Book patent estate exists for carisbamate because no carisbamate product has been approved and listed in the Orange Book.
Patent protection and expiration
| Patent category | Relevance to carisbamate | Current commercial effect |
|---|---|---|
| Composition-of-matter patents | Could cover carisbamate and related chemical structures | May have expired or be approaching the end of enforceable life, depending on filing date and jurisdiction |
| Formulation patents | Could cover dosage forms, excipients or release characteristics | No Orange Book enforcement position without an approved product |
| Method-of-use patents | Could cover treatment of epilepsy or seizure subtypes | No marketed indication to enforce |
| Manufacturing patents | Could cover synthesis, intermediates or purification | Could remain relevant to process replication, but does not block all alternative synthesis routes |
| Patent-term extensions | Potentially available only after regulatory approval | No known commercial benefit because carisbamate was not approved |
| Pediatric exclusivity | Requires an approved product and qualifying FDA request | Not applicable |
Specific patent numbers, expiration dates and legal status must be assessed from national patent registers and the relevant assignee records. Publicly available development records do not establish a current, enforceable commercial barrier comparable to an approved product’s Orange Book-listed patents.
When does carisbamate lose exclusivity?
Carisbamate did not have a commercial exclusivity date because it never reached FDA approval.
Any original composition-of-matter patent rights would have been calculated from their filing dates, generally under the 20-year U.S. patent term framework, subject to patent-term adjustment, terminal disclaimers, prosecution history and jurisdiction-specific rules. Those patent terms are distinct from FDA exclusivity.
The absence of approval has two consequences:
- There is no branded launch date from which generic substitution rights can be measured.
- There is no statutory generic-entry event comparable to a Paragraph IV challenge against an approved reference product.
Have companies filed Paragraph IV challenges against carisbamate?
No commercially meaningful Paragraph IV challenge has been identified.
Paragraph IV litigation is typically initiated when a generic applicant files an ANDA challenging an Orange Book-listed patent covering an approved reference drug. Carisbamate has no approved reference product and no identified Orange Book-listed patent set. A conventional Paragraph IV pathway is therefore not available for a nonexistent branded reference product (U.S. Food and Drug Administration, n.d.-a; U.S. Food and Drug Administration, n.d.-b).
Which companies are challenging carisbamate?
No active generic challenger has been publicly established. No major generic manufacturer has publicly announced an ANDA-based carisbamate launch strategy.
Potential future entrants would face development risk rather than ordinary generic substitution risk. A sponsor seeking to commercialize carisbamate would need to establish regulatory approval, clinical utility and manufacturing controls before competing for prescriptions.
What patent litigation affects carisbamate?
No active, high-value patent litigation involving an approved carisbamate product has been identified in the public record.
The lack of litigation is consistent with the asset’s status. There is no marketed product generating sales that would justify a major patent dispute, and no approved reference product creating a conventional ANDA litigation pathway.
Are there settlement agreements involving carisbamate?
No material patent settlement agreement involving a carisbamate generic launch has been publicly established. Settlement structures such as delayed-entry agreements, authorized generic arrangements or shared commercialization rights generally arise after approval and commercial sales. Those conditions did not develop for carisbamate.
What formulations are protected by carisbamate patents?
Carisbamate was evaluated as an oral small-molecule therapy. Public clinical descriptions support oral tablet development, but no approved commercial formulation exists.
Potential formulation protection could have covered:
- Immediate-release oral tablets
- Dose strengths used in adjunctive epilepsy trials
- Excipients and tablet composition
- Solid-state or crystalline forms
- Manufacturing processes
- Stability and impurity controls
These categories should not be treated as evidence of an active blocking position. Formulation patents have value only when they protect a product that is clinically viable, approved and commercially demanded.
How strong is the carisbamate patent estate?
The estate has low current commercial strength.
Its historical value may have been meaningful during Phase II and Phase III development, when composition-of-matter rights could have supported exclusivity if the product had been approved. That value declined sharply after clinical discontinuation.
| Patent-estate factor | Assessment |
|---|---|
| Composition-of-matter value | Historically potentially strong; current value reduced by age and lack of product |
| Regulatory linkage | Weak, because there is no approved product |
| Formulation protection | Potentially relevant but commercially untested |
| Method-of-use protection | Limited without an approved indication |
| Manufacturing barriers | Possible, but unlikely to independently create a large market |
| Litigation leverage | Low |
| Licensing leverage | Low unless supported by new clinical data |
| Overall current strength | Low |
The most important barrier is not patent expiration. It is the absence of regulatory validation and clinical proof.
What is the market projection for carisbamate?
The base-case market projection is zero near-term revenue.
Carisbamate has no approved product, no active commercial supply chain and no established reimbursement status. A market could emerge only after a sponsor restarts development, confirms a clinically meaningful treatment effect and obtains approval.
Carisbamate market scenarios
| Scenario | Probability profile | Market outcome |
|---|---|---|
| Base case: no redevelopment | Most commercially probable | No sales and no addressable branded market |
| Academic or investigator-led revival | Possible but limited | Clinical activity without material revenue |
| Strategic licensing and redevelopment | Low probability | Small opportunity if new data show differentiation |
| Full regulatory revival | Low probability | Specialty epilepsy product with uncertain uptake |
| Broad label expansion | Very low probability | Requires new trials and a differentiated mechanism or benefit |
A revived carisbamate product would enter a crowded antiseizure market. The largest commercial opportunity would likely be in drug-resistant focal epilepsy, where unmet need remains but prescribing is controlled by efficacy, tolerability, interactions and payer restrictions.
What would a revived carisbamate product need to generate sales?
A new sponsor would need to demonstrate at least one clear advantage:
- Superior seizure reduction against current adjunctive treatments
- Lower cognitive or psychiatric burden
- Fewer pharmacokinetic interactions
- Better tolerability at effective doses
- Convenient once-daily dosing
- Utility in a treatment-resistant subgroup
- Evidence for monotherapy or another commercially valuable indication
Without differentiation, carisbamate would likely face generic competition from established antiseizure therapies and limited physician switching.
How does carisbamate compare with current epilepsy drugs?
| Drug or category | Regulatory status | Market position relative to carisbamate |
|---|---|---|
| Levetiracetam | Approved and widely genericized | Strong prescribing familiarity and low cost |
| Lamotrigine | Approved and genericized | Established efficacy with broad use |
| Lacosamide | Approved, with generic competition | Stronger commercial and regulatory position |
| Cenobamate | Approved for focal seizures | Demonstrated differentiation in refractory epilepsy |
| Brivaracetam | Approved for focal seizures | Branded and generic competition |
| Carisbamate | Unapproved | No market access or prescribing base |
Cenobamate is the closest strategic comparator among newer focal-seizure therapies because it reached approval with evidence in drug-resistant epilepsy. Carisbamate lacks the regulatory validation, clinical momentum and commercial infrastructure that support cenobamate.
What are the generic launch risks for carisbamate?
Generic launch risk is currently theoretical rather than operational.
If a sponsor obtained approval, generic competition would depend on the surviving patent estate, any newly granted formulation or use patents, regulatory exclusivity and the timing of ANDA filings. A future carisbamate product could face:
- Early competition if composition patents have expired
- Limited protection if only narrow formulation claims remain
- Weak pricing power in a generic-heavy epilepsy market
- Payer pressure favoring established low-cost alternatives
- Physician reluctance to adopt a previously discontinued molecule
- Manufacturing competition if synthesis is straightforward
A new approval without meaningful exclusivity would have a weak commercial profile.
What licensing or acquisition opportunities exist for carisbamate?
No significant current licensing or acquisition transaction has established carisbamate as an active partnering asset.
A transaction would likely depend on access to historical clinical data, remaining patent rights, manufacturing know-how and a credible development plan. The discontinued Phase III history would reduce valuation and require a sponsor to explain why a new trial design, patient population or formulation could produce a different outcome.
A license would have greater strategic value if it included:
- Complete clinical and nonclinical data packages
- Rights to global patent families
- Manufacturing and analytical methods
- Freedom-to-operate analysis
- Biomarker or responder-subgroup information
- A defined regulatory strategy
Absent those assets, carisbamate is more likely to be treated as an abandoned clinical program than as a near-term licensing opportunity.
What is the competitive outlook for carisbamate?
The competitive outlook is unfavorable.
The epilepsy market has established generic medicines, approved branded products and newer agents with completed clinical programs. Carisbamate would need to overcome both its discontinued development history and the opportunity cost of prescribing a product without a demonstrated advantage.
The main strategic value may be historical rather than commercial. Its clinical data could inform antiseizure drug development, mechanism research or subgroup analysis, but that does not create a near-term product market.
Key Takeaways
- Carisbamate, also known as RWJ-333369, is an unapproved investigational antiseizure drug.
- Development reached Phase III for adjunctive treatment of partial-onset seizures.
- The program was discontinued after unfavorable late-stage development results.
- There is no FDA approval, Orange Book listing, marketed brand or active generic market.
- No meaningful Paragraph IV challenge, generic settlement or commercial patent litigation has been identified.
- Current patent strength is low because there is no approved product to support exclusivity or litigation leverage.
- Near-term revenue projection is zero.
- A commercial revival would require new clinical evidence and a clear advantage over generic antiseizure drugs and approved newer agents.
- The probability of a major commercial launch is low without a new sponsor, new trial strategy and differentiated efficacy or tolerability data.
FAQs About Carisbamate Development and Market Potential
Is carisbamate the same as cenobamate?
No. Carisbamate is RWJ-333369, while cenobamate is YKP3089. Cenobamate was approved for focal seizures; carisbamate was discontinued before approval.
Can carisbamate still be prescribed in the United States?
No approved commercial carisbamate product is available for routine U.S. prescribing. Access, if any, would require an applicable investigational or special-access pathway.
Did Johnson & Johnson launch a carisbamate brand?
No. Johnson & Johnson and affiliated development organizations studied carisbamate, but no branded product was launched.
Could carisbamate be repurposed for migraine?
There is no established FDA-approved migraine indication or commercial migraine development program for carisbamate. Repurposing would require new clinical evidence.
Does carisbamate have biosimilar risk?
No. Carisbamate is a small-molecule drug, not a biologic. Biosimilar rules do not apply. Any future competition would involve generic-drug or new-drug pathways.
References
ClinicalTrials.gov. (n.d.-a). A study of carisbamate in patients with partial onset seizures. U.S. National Library of Medicine. https://clinicaltrials.gov/
ClinicalTrials.gov. (n.d.-b). Clinical studies of RWJ-333369/car isbamate in epilepsy. U.S. National Library of Medicine. https://clinicaltrials.gov/
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.-b). Abbreviated new drug application (ANDA) submissions and Paragraph IV patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-submissions
U.S. National Library of Medicine. (n.d.). PubMed database: Carisbamate and RWJ-333369 clinical research. https://pubmed.ncbi.nlm.nih.gov/
More… ↓
